Serum Growth Differentiation Factor 15 Levels in Newly Diagnosed Multiple Myeloma Patients

Publisher： Karger

E-ISSN： 1421-9662|131|3|173-178

ISSN： 0001-5792

Source： Acta Haematologica, Vol.131, Iss.3, 2013-11, pp. : 173-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Growth Differentiation Factor 15 in Multiple Myeloma: A Microenvironment Factor Predictive of Response to Treatment?

By  

Acta Haematologica, Vol. 131, Iss. 3, 2013-11 ,pp. : 170-172

Karger

Access to resources Recommend Favorite

A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 140-145

Karger

Access to resources Recommend Favorite

Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard‐risk cytogenetics

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 523-531

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 361-8609, Iss. 10, 2015-10 ,pp. : 888-891

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 229-230

Karger

Access to resources Recommend Favorite